{
    "code": 0,
    "data": [
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2025",
            "news_body": "Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31.12.2025.",
            "news_id": "1bfd8813-481d-4e24-b483-dd87944aa7f1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56515797-ca90-4745-a79a-b2e953f9a644.pdf",
            "news_date": "2026-02-12 11:38:22",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025",
            "news_body": "UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025",
            "news_id": "3575f9ea-2307-4d78-8ca2-4e1a7b649403",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12d9b317-3026-42f6-a947-5951468b0e3a.pdf",
            "news_date": "2025-11-13 12:33:12",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "UN AUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 30-JUNE-2025",
            "news_body": "UN AUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 30-JUNE-2025.",
            "news_id": "0b609264-bfff-40e9-a499-0218f430462e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9938645-4db6-43ff-97e0-ce7b4619dcc8.pdf",
            "news_date": "2025-08-07 12:55:57",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Year Ended 31St March 2025\r\n",
            "news_body": "Audited Financial Results for the Quarter and Year Ended 31st March 2025",
            "news_id": "1be88f28-e74b-4723-9e53-508bffbc3462",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9043464d-4b90-421e-8b38-f8414f6a5599.pdf",
            "news_date": "2025-05-22 12:36:35",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024\r\n",
            "news_body": "UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31.12.2024\r\n",
            "news_id": "0b4f205d-9972-4e25-a1f4-566786b7781e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58414f1a-44fd-424b-ba32-557aa08b8ba3.pdf",
            "news_date": "2025-02-13 12:21:13",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2024",
            "news_body": "UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2024",
            "news_id": "3fa3c40f-ee77-495b-8929-bcc94ede9292",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=126956bc-f771-4bd2-b4fa-302a9eca98fa.pdf",
            "news_date": "2024-11-14 12:21:58",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended 30-June-2024",
            "news_body": "Un-Audited Financial Results for the Quarter Ended 30-June-2024",
            "news_id": "2bc37fe5-2da6-46d1-a660-8a9787442c47",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa9c4157-b16a-4ae1-aa07-8883654fa228.pdf",
            "news_date": "2024-08-08 12:10:18",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , we attach herewith transcript of Conference Call held on May 16, 2024 . A copy of the same is available on the website of the Company.",
            "news_id": "c8ca6f60-29e4-497b-9863-50925fe451cb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=08f8b461-6548-4a68-8a3d-f0456f03d61c.pdf",
            "news_date": "2024-05-18 17:12:31",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For Quarter And Year Ended 31St March, 2024",
            "news_body": "Audited Financial Results for Quarter and year Ended 31st March,2024.",
            "news_id": "5b11816f-c827-4413-a732-8c88c58bdd73",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9049dd4-85a9-40d1-ab8e-23ef22c27b97.pdf",
            "news_date": "2024-05-16 12:14:59",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results Of The Company<BR> <BR>",
            "news_body": "Considered and approved un-audited financial results (standalone and consolidated) of the Company along with limited review reports for the Quarter and Nine Months ended on December 31, 2023.",
            "news_id": "75f7052b-f969-4148-8089-affa1aac7f68",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d512ae99-cea7-487f-89c6-fb236805ee45.pdf",
            "news_date": "2024-02-08 12:28:43",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE BOARD MEETING",
            "news_body": "OUTCOME OF THE BOARD MEETING",
            "news_id": "924993dc-2e89-4150-8c2e-91b45a211d94",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a734abf-ace5-4415-b774-3487bc1bb28e.pdf",
            "news_date": "2024-02-08 12:22:43",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For Quarter And Half Year Ended On 30.09.2023",
            "news_body": "Un-Audited Financial Results for Quarter and Half year ended on 30.09.2023",
            "news_id": "805c0dea-2324-40d3-b890-bfc5988fb09a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2f6cae7-a7ec-4e61-9d56-5925179152cb.pdf",
            "news_date": "2023-11-02 12:24:29",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Un-Audited Financial Results for the Quarter and half year ended 30.09.2023",
            "news_id": "48d54030-6190-4bde-81e8-ae20a60fd26c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21ed9d5f-4d9d-4610-b9b1-2be0d2097bf0.pdf",
            "news_date": "2023-11-02 12:20:30",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30.06.2023.",
            "news_body": "Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended 30.06.2023",
            "news_id": "36f48dac-8b82-4fd8-bda0-7690e37b9adf",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fa011d6-f470-45a5-a896-f31780213341.pdf",
            "news_date": "2023-08-10 12:22:23",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023",
            "news_body": "FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023",
            "news_id": "ca0cfc97-40b1-453e-8ccf-f0dc5acd12d6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50d401bd-be28-48a2-8497-4ff77a061264.pdf",
            "news_date": "2023-05-25 11:42:47",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2023",
            "news_body": "Financial Results (standalone and consolidated) for the Quarter and Year Ended March 31, 2023",
            "news_id": "3b21ee8f-4e00-440c-9de9-53f888a758ee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6280846-0d2c-4011-b8ad-1f08388f13be.pdf",
            "news_date": "2023-05-25 11:37:58",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results Of The Company<BR>",
            "news_body": "To Consider and approved un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and nine months ended on December 31, 2022. <BR>",
            "news_id": "1ab38f4b-e747-44f4-b0e9-27650f74d1ec",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0608f114-16be-4307-b2ee-5a98ce7271c5.pdf",
            "news_date": "2023-02-09 12:55:56",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF BOARD MEETING<BR>",
            "news_body": "Outcome of the Board Meeting held today",
            "news_id": "ef7396fb-41e1-42b3-869b-78b15aab4283",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b322aa59-25e6-4da5-821c-5bf84de305a4.pdf",
            "news_date": "2023-02-09 12:51:39",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.",
            "news_body": "Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
            "news_id": "97db2e09-0cff-495d-8fcf-aeb3323a2389",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f55b3bc-73e3-4967-a297-4f2a759cc77f.pdf",
            "news_date": "2022-11-24 15:30:22",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On 30.09.2022",
            "news_body": "Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended on 30.09.2022<BR>",
            "news_id": "13e8951f-ec90-4725-ba07-c7d2425c1be8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc6bda25-f17e-43ff-bcc4-9b13945ba8cc.pdf",
            "news_date": "2022-11-10 11:28:15",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "FINANCIAL RESULTS FOR QUARTER ENDED 30.06.22",
            "news_body": "FINANCIAL RESULTS FOR QUARTER ENDED 30.06.22",
            "news_id": "1a944a33-ac08-47a1-af93-86e0f78465a0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a3c737b-d56d-4d09-bdfa-7d521d84952a.pdf",
            "news_date": "2022-08-09 13:29:19",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Regulation 23(9)-Disclosure Of Related Party Transactions",
            "news_body": "In compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of related party transactions in the specified format for the half year ended March 31, 2022. The same available on the website of the Company at www.lincolnpharma.com",
            "news_id": "8a89af95-955b-42f5-8e34-573d79e6e737",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90129449-ace7-4f67-8c28-08ee0360239b.pdf",
            "news_date": "2022-06-02 11:40:24",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Result For The Quarter And Year Ended March 31, 2022",
            "news_body": "board consider audited financial result (standalone & consolidated) for the quarter and year ended March 31, 2022.",
            "news_id": "8cc77fe0-de7d-45dd-b364-8c7fc6de6451",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a89c535c-95e1-45d0-bb2f-962f61238623.pdf",
            "news_date": "2022-05-19 13:10:40",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "d1192d92-ffef-4671-b788-4719ed242a55",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e60f4779-504b-4f2f-9631-d9d018bec341.pdf",
            "news_date": "2022-05-19 12:49:02",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results Of The Company",
            "news_body": "To Consider and approved un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and nine months ended on December 31, 2021.",
            "news_id": "8cf4d91c-c971-4029-bbac-e43d71dd0267",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7bb9a00-d7e3-4531-8048-8ad3406f3cf8.pdf",
            "news_date": "2022-02-10 13:02:11",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On September 30, 2021",
            "news_body": "Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 11, 2021, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and half year ended on September 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.",
            "news_id": "a05fc0d4-1793-47fa-8b49-12ace2e39033",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91d18558-aa8e-4763-b1d8-2e6ea07a4baa.pdf",
            "news_date": "2021-11-11 12:54:41",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 11, 2021, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and half year ended on September 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.",
            "news_id": "8a181142-d068-4716-bc8d-7fd28d7aa4e4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27b58009-134c-4e86-8449-1fddbbfe8a83.pdf",
            "news_date": "2021-11-11 12:51:05",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Result For The Quarter Ended June 30, 2021",
            "news_body": "We would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, August 10, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter ended on June 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.",
            "news_id": "b79e3229-3b66-4882-8962-bb4117c3360b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28524dbb-a447-4266-a19f-56bb38030323.pdf",
            "news_date": "2021-08-10 12:40:00",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "We would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, August 10, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter ended on June 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.",
            "news_id": "defa1f40-8371-43bc-b637-c6fda2032c15",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7e518e0c-af61-4569-ba3f-a9c54317de62.pdf",
            "news_date": "2021-08-10 12:36:41",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Regulation 23 (9) - Disclosure Of Related Party Transaction For The Half Year Ended On March 31, 2021",
            "news_body": "Pursuant to Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions on a consolidated basis, in the format specified in the relevant Indian accounting standards for the half year ended March 31, 2021.",
            "news_id": "1bd81328-363f-405e-a2d1-12d3d8181784",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4517edd3-1bc8-4511-8a58-f2454a686a13.pdf",
            "news_date": "2021-06-18 12:42:10",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LINCOLN",
            "disp": "Lincoln Pharmaceuticals",
            "bse_code": 531633,
            "isin": "INE405C01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Result For The Quarter And Year Ended March 31, 2021",
            "news_body": "we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 25, 2021, have considered / approved / recommended, inter alia, the followings: (1) audited financial results (standalone and consolidated) for the quarter and year ended<BR> on March 31, 2021 along with the reports of auditors thereon. Recommended a dividend qf ~ 1.50/- (i.e. 15% per share) per equity share of face value of ~ 10.00/- for<BR> the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting<BR> (AGM) of the Company. We also enclose herewith financial highlights of the Company for the aforesaid quarter.",
            "news_id": "33e4d390-3e6a-415d-b4ce-b714e131051c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7cfd01ee-55fb-4063-8875-915cdc19c967.pdf",
            "news_date": "2021-05-25 12:55:41",
            "seo": "lincoln-pharmaceuticals-ltd",
            "ltp": 528.85,
            "ch": -6.2999999999999545,
            "pch": -1.177240026160881,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 11596,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}